<!DOCTYPE html>
<html>
  <head>
    <meta charset="utf-8"/>
    <meta property="og:url" content="https://www.thecerbatgem.com/2019/11/24/dr-reddys-laboratories-nyserdy-upgraded-to-sell-by-valuengine.html"/>
    <meta property="og:site_name" content="The Cerbat Gem"/>
    <meta property="article:published_time" content="2019-11-24T10:33:00+00:00"/>
    <meta property="og:title" content="Dr.Reddy’s Laboratories (NYSE:RDY) Upgraded to “Sell” by ValuEngine"/>
    <meta property="og:description" content="ValuEngine upgraded shares of Dr.Reddy’s Laboratories (NYSE:RDY) from a strong sell rating to a sell rating in a report published on Wednesday, ValuEngine reports. A number of other research firms also recently weighed in on RDY. TheStreet upgraded Dr.Reddy’s Laboratories from a c rating to a b- rating in a report on Thursday, August 15th. […]"/>
  </head>
  <body>
    <article>
      <h1>Dr.Reddy’s Laboratories (NYSE:RDY) Upgraded to “Sell” by ValuEngine</h1>
      <address><time datetime="2019-11-24T10:33:00+00:00">24 Nov 2019, 10:33</time> by <a rel="author" href="https://www.thecerbatgem.com/author/renee" target="_blank">Renee Jackson</a></address>
      <figure>
        <img src="https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?w=250&amp;zc=1&amp;src=https://www.marketbeat.com/logos/dr-reddys-laboratories-limited-logo.png"/>
      </figure>
      <p><a href="https://www.americanconsumernews.net/scripts/click.aspx?ValuEngine=1&amp;Symbol=RDY">ValuEngine</a> upgraded shares of Dr.Reddy’s Laboratories (NYSE:RDY) from a strong sell rating to a sell rating in a report published on Wednesday, <a href="https://www.valuengine.com/">ValuEngine</a> reports.</p>
      <p>A number of other research firms also recently weighed in on RDY. TheStreet upgraded Dr.Reddy’s Laboratories from a c rating to a b- rating in a report on Thursday, August 15th. Bank of America downgraded Dr.Reddy’s Laboratories from a buy rating to a neutral rating in a report on Monday, November 4th. Finally, Credit Suisse Group upgraded Dr.Reddy’s Laboratories from an underperform rating to an outperform rating in a report on Wednesday, September 4th. Two investment analysts have rated the stock with a sell rating, four have given a hold rating and four have assigned a buy rating to the company’s stock. Dr.Reddy’s Laboratories presently has an average rating of Hold and an average price target of $39.50.</p>
      <p><a href="https://www.marketbeat.com/stocks/NYSE/RDY/price-target/">RDY</a> traded down $0.60 during midday trading on Wednesday, reaching $39.70. 170,789 shares of the company’s stock traded hands, compared to its average volume of 150,003. Dr.Reddy’s Laboratories has a 52 week low of $34.67 and a 52 week high of $42.82. The firm has a fifty day moving average of $38.78 and a two-hundred day moving average of $37.96. The company has a debt-to-equity ratio of 0.10, a current ratio of 1.96 and a quick ratio of 1.39. The stock has a market capitalization of $6.68 billion, a price-to-earnings ratio of 17.52 and a beta of 0.22.</p>
      <p>Hedge funds have recently bought and sold shares of the business. Bank of New York Mellon Corp grew its holdings in shares of Dr.Reddy’s Laboratories by 20.1% during the 2nd quarter. Bank of New York Mellon Corp now owns 27,401 shares of the company’s stock worth $1,027,000 after acquiring an additional 4,587 shares during the period. Atria Investments LLC purchased a new stake in shares of Dr.Reddy’s Laboratories in the 2nd quarter worth approximately $171,000. Panagora Asset Management Inc. grew its stake in shares of Dr.Reddy’s Laboratories by 8.2% in the 2nd quarter. Panagora Asset Management Inc. now owns 116,084 shares of the company’s stock worth $4,349,000 after buying an additional 8,836 shares during the last quarter. Bank of America Corp DE grew its stake in shares of Dr.Reddy’s Laboratories by 1.0% in the 2nd quarter. Bank of America Corp DE now owns 188,488 shares of the company’s stock worth $7,062,000 after buying an additional 1,859 shares during the last quarter. Finally, Marshall Wace North America L.P. purchased a new stake in shares of Dr.Reddy’s Laboratories in the 2nd quarter worth approximately $314,000. Hedge funds and other institutional investors own 13.31% of the company’s stock.</p>
      <p>
        <b>About Dr.Reddy’s Laboratories</b>
      </p>
      <p>Dr. Reddy's Laboratories Limited operates as an integrated pharmaceutical company worldwide. It operates through three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosage with therapeutic equivalence to branded formulations.</p>
      <p>Featured Story: <a href="https://www.marketbeat.com/financial-terms/what-is-meant-by-holder-of-record/">What is meant by holder of record?</a></p>
      <p>To view ValuEngine’s full report, visit <a href="https://www.valuengine.com/rep/order_report?pid=64&amp;srchfor=RDY">ValuEngine’s official website</a>.</p>
      <figure>
        <img src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NYSE&amp;Symbol=RDY"/>
      </figure>
    </article>
  </body>
</html>